SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-17-008925
Filing Date
2017-05-05
Accepted
2017-05-05 06:05:23
Documents
46
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fprx-10q_20170331.htm 10-Q 1275569
2 EX-10.1 fprx-ex101_214.htm EX-10.1 290174
3 EX-31.1 fprx-ex311_6.htm EX-31.1 8502
4 EX-31.2 fprx-ex312_8.htm EX-31.2 8498
5 EX-32.1 fprx-ex321_7.htm EX-32.1 5341
6 EX-32.2 fprx-ex322_9.htm EX-32.2 5234
7 GRAPHIC g201705042209585594703.jpg GRAPHIC 56102
  Complete submission text file 0001564590-17-008925.txt   4520048

Data Files

Seq Description Document Type Size
8 XBRL INSTANCE DOCUMENT fprx-20170331.xml EX-101.INS 913594
9 XBRL TAXONOMY EXTENSION SCHEMA fprx-20170331.xsd EX-101.SCH 24547
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fprx-20170331_cal.xml EX-101.CAL 40472
11 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fprx-20170331_def.xml EX-101.DEF 66340
12 XBRL TAXONOMY EXTENSION LABEL LINKBASE fprx-20170331_lab.xml EX-101.LAB 217222
13 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fprx-20170331_pre.xml EX-101.PRE 158581
Mailing Address TWO CORPORATE DRIVE SOUTH SAN FRANCISCO CA 94080
Business Address TWO CORPORATE DRIVE SOUTH SAN FRANCISCO CA 94080 415-365-5600
FIVE PRIME THERAPEUTICS INC (Filer) CIK: 0001175505 (see all company filings)

IRS No.: 260038620 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36070 | Film No.: 17816017
SIC: 2834 Pharmaceutical Preparations